Disappointing study results for Athersys

Athersys Inc. (Nasdaq: ATHX) reported disappointing results from a Phase 2 study of its MultiStem cell therapy to treat ischemic stroke patients sending the stock price tumbling 87 cents to $1.31.


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.